L3VLUP
ProSign in

COLL in the 13F filings

Collegium Pharmaceutical Inc · CUSIP 19459J104

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
31 Mar 2024
the date the book describes
Filed
15 May 2024
latest of these filings; the earliest 13 May 2024
Managers listing it
4
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q4 2023 and Q1 2024; 1 listed it in both
Shares listed
1,514,005
combined, among listed positions
Reported value
$59m
combined, at the quarter end

Among the 93 comparable managers: 4 buyers (opened or added shares) and 0 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +129,407.

Managers listing COLL in Q1 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q4 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

4 of 4 holders

ActionFiling
Renaissance Technologies LLC1,418,198$55m0.09%Added+33,60013 May 2024 (the filing on sec.gov)
Caxton Associates LLP44,565$1.7m0.10%Newnew15 May 2024 (the filing on sec.gov)
Winton Group Ltd42,369$1.6m0.12%Newnew14 May 2024 (the filing on sec.gov)
Maverick Capital Ltd8,873$344kunder 0.1%Newnew15 May 2024 (the filing on sec.gov)

Largest increases and reductions, by shares

Q4 2023 to Q1 2024, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (3)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q3 2024 to 4 in Q2 2026

Tracked managers listing it, at least.

02462017201820192020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
COLL by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20161$282kn.a.n.a.
Q3 20161$458kn.a.n.a.
Q4 20161$1.9mn.a.n.a.
Q1 20171$1.0mn.a.n.a.
Q2 20172$1.5mn.a.n.a.
Q3 20171$525kn.a.n.a.
Q4 20172$64mn.a.n.a.
Q1 20182$99mn.a.n.a.
Q2 20183$102mn.a.n.a.
Q3 20182$9.3mn.a.n.a.
Q4 20182$74mn.a.n.a.
Q1 20191$6.0mn.a.n.a.
Q2 20191$721kn.a.n.a.
Q3 20191$502kn.a.n.a.
Q4 20193$99mn.a.n.a.
Q1 20202$90mn.a.n.a.
Q2 20202$93mn.a.n.a.
Q3 20202$110mn.a.n.a.
Q4 20202$103mn.a.n.a.
Q1 20212$98mn.a.n.a.
Q2 20213$99mn.a.n.a.
Q3 20211$81mn.a.n.a.
Q4 20212$71mn.a.n.a.
Q1 20221$1.1mn.a.n.a.
Q2 20222$40mn.a.n.a.
Q3 20223$32mn.a.n.a.
Q4 20223$35mn.a.n.a.
Q1 20232$31mn.a.n.a.
Q2 20231$224kn.a.n.a.
Q3 20231$26mn.a.n.a.
Q4 20231$43m10
Q1 20244$59m40
Q2 20243$52m30
Q3 20242$67m21
Q4 20242$48m11
Q1 20252$54m11
Q2 20251$45m01
Q3 20255$60m40
Q4 20256$209m1814
Q1 20265$157m1615
Q2 20264$180m1118

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

COLL and LLY →COLL and JNJ →COLL and VRTX →Choose a stock to compare with COLL →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own COLL, latest filings →Back to the 13F Explorer →